The Pah-R261Q mouse model thus represents a unique research tool to support the evaluation and discovery of additional biomarkers in PKU and to investigate mutation-specific comorbidities, of benefit to the large number of PKU patients harboring the R261Q mutation. This evidence concerns the gene PAH and phenylketonuria.